

## Claims

1. An antibody that specifically binds to mesothelin (MSLN), comprising:

a light chain variable domain (VL domain) consisting of a sequence having an amino acid sequence of SEQ ID NO: 1; and

a heavy chain variable domain (VH domain) consisting of a sequence having an amino acid sequence of any one of SEQ ID NOs: 3 to 5;

wherein the antibody is a humanized antibody.

~~2. The antibody of claim 1, wherein the antibody specifically binds to mesothelin (MSLN).~~

~~3~~2. The antibody of claim ~~2~~1, wherein the MSLN is human MSLN.

~~4~~3. The antibody of claim 1, wherein the antibody specifically binds to a MSLN-expressing cancer cell.

~~5~~4. The antibody of claim ~~4~~3, wherein the MSLN-expressing cancer cell is a human cancer cell.

20

~~6~~5. A polynucleotide that encodes the light chain variable domain (VL domain) and the heavy chain variable domain (VH domain) of the antibody of claim 1.

~~7~~6. An expression vector comprising the polynucleotide of claim ~~6~~5.

87. A host cell transformed with the expression vector of claim 76.

5 98. A method for producing an antibody that specifically binds to MSLN,  
comprising culturing the host cell of claim 87.

109. A pharmaceutical composition for use in preventing or treating cancer,  
comprising the antibody of claim 1 ~~or an antigen-binding fragment thereof~~.

10 ~~11~~10. The pharmaceutical composition for use according to ~~of~~ claim ~~109~~,  
wherein the cancer is mesothelioma, pancreatic cancer, ovarian cancer, gastric cancer,  
lung cancer, or endometrial cancer.

15 ~~12~~11. The antibody of claim 1 for use in preventing or treating cancer.

~~13~~12. A use of the antibody of claim 1 in the manufacture of a medicament  
for preventing or treating cancer.